// App-Quantinova.ai

: Bimekizumab treatment response is maintained up to 3 years in patients with psoriatic arthritis: responder analyses from BE ACTIVE, a phase 2b dose-ranging study, and its open-label extension

Researchers

Presenter

  • Joseph F. Merola

Principal Investigators

  • Akihiko Asahina

  • Christopher T. Ritchlin

  • Barbara Ink

  • Deepak Assudani

  • Rajan Bajracharya

  • Jason Coarse

  • Jason Eells

  • Philip J. Mease

Medical Centers

  • Harvard Medical School, Brigham and Women's Hospital, Boston, MA.

  • Department of Surgery, The Jikei University of Medicine, Tokyo, Japan

  • University of Rochester, Department of Medicine, Rochester, NY, USA

  • UCB Pharma, Slough

  • UCB Pharma, Raleigh, NC

  • Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

Locations

  • United States

  • Japan

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • bimekizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • II

Study Id's

  • NCT02969525

  • NCT03347110

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved